Bio-Rad Laboratories (BIO) Cash from Financing Activities (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Cash from Financing Activities for 18 consecutive years, with -$27.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 79.75% year-over-year to -$27.6 million in Q2 2026; TTM through Jun 2026 was -$120.8 million, a 66.09% increase from a year earlier, with the FY2025 full-year figure at -$283.2 million, down 29.43% from the prior year.
• Cash from Financing Activities was -$27.6 million for Q2 2026 at Bio-Rad Laboratories, up from -$44.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $1.2 billion in Q1 2022 and troughed at -$202.7 million in Q2 2023.
• A 5-year average of -$1.5 million and a median of -$52.5 million in 2025 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 2613.98% in 2022, down 4334.76% in 2022.
• Over 5 years, Cash from Financing Activities stood at -$86.6 million in 2022, then slumped by 131.62% to -$200.6 million in 2023, then surged by 86.94% to -$26.2 million in 2024, then surged by 112.6% to $3.3 million in 2025, then tumbled by 936.36% to -$27.6 million in 2026.
• The last three Cash from Financing Activities figures came in at -$27.6 million (Q2 2026), -$44.0 million (Q1 2026), and $3.3 million (Q4 2025), per Business Quant data.